DETERMINANTS OF SURVIVAL IN IDIOPATHIC PULMONARY FIBROSIS

被引:257
|
作者
SCHWARTZ, DA
HELMERS, RA
GALVIN, JR
VANFOSSEN, DS
FREES, KL
DAYTON, CS
BURMEISTER, LF
HUNNINGHAKE, GW
机构
[1] VET ADM MED CTR,DEPT INTERNAL MED,DIV PULM DIS,IOWA CITY,IA 52240
[2] VET ADM MED CTR,DEPT RADIOL,IOWA CITY,IA
关键词
D O I
10.1164/ajrccm.149.2.8306044
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
To identify the determinants of survival in patients with idiopathic pulmonary fibrosis (IPF), we performed a survival analysis on 74 subjects with IPF. The study subjects were on average 64 yr of age (range, 25 to 83 yr), 62% were male, and 29% were never smokers. A tissue diagnosis was made in 67 (91%) of our study subjects. These subjects were followed for a mean period of 4 yr (range, 1.4 to 118.8 months) after the onset of pulmonary symptoms. During the period of observation, 41 subjects died (median survival = 28.2 months) and 33 continue to survive (median follow-up period = 60.9 months). A univariate analysis demonstrated that diminished survival was significantly associated with male gender (hazard ratio = 1.98; 95% confidence interval [CI] = 1.01-3.85), a higher FEV(1)/FVC ratio (hazard ratio = 1.82 [per 10% increase in the FEV(1)/FVC ratio]; 95% CI = 1.21-2.73), a lower percent predicted FVC (hazard ratio = 0.74; 95% CI = 0.60-0.91), a lower percent predicted total lung capacity (TLC) (hazard ratio = 0.75; 95% CI = 0.60-0.94), a lower percent predicted diffusing capacity of carbon monoxide (DL(CO)) (hazard ratio = 0.69; 95% CI = 0.53-0.89), a higher ILO profusion category on chest radiograph (hazard ratio = 3.52; 95% CI = 1.58-7.87), and an enhanced release of prostaglandin E(2) (PGE(2)) by cultured alveolar macrophages (hazard ratio = 1.32 [per 10 pm/ml of PGE(2)]; 95% CI = 1.07-1.62). In fact, after controlling for age, Cox's regression analyses demonstrated that diminished survival was independently associated with male gender (hazard ratio = 9.05; 95% CI = 1.84-44.5), a higher FEV(1)/FVC ratio (hazard ratio = 3.91 [per 10% increase in the FEV(1)/FVC ratio]; 95% CI = 1.68-8.07), and an enhanced release of PGE(2) by cultured alveolar macrophages (hazard ratio = 1.45 [per 10 pm/ml of PGE(2)]; 95% CI = 1.14-1.83). Survival was not found to be independently associated with the concentration of cells in the ravage fluid or other cytokines (tumor necrosis factor alpha [TNF alpha] and interleukin-1 beta [IL-1 beta]) released by alveolar macrophages. Limiting our analysis to subjects closely followed in our SCOR Program (n = 41), Cox's regression analysis (adjusted for age) demonstrated that diminished survival was independently associated with male gender (hazard ratio = 8.21; 95% CI = 1.30-50.6), a higher ILO profusion category (hazard ratio = 4.00; 95% CI = 1.43-11.42), and a lower concentration of lymphocytes in bronchoalveolar ravage fluid (hazard ratio = 0.95; 95% CI = 0.91-0.99). In aggregate, our findings suggest that adverse prognosticators in IPF include male gender, advanced disease (restrictive lung function, abnormal gas exchange, and increased interstitial abnormalities on the chest radiograph), and, possibly, increased release of PGE(2) from cultured alveolar macrophages.
引用
下载
收藏
页码:450 / 454
页数:5
相关论文
共 50 条
  • [31] Quantitative CT Analysis And Survival In Idiopathic Pulmonary Fibrosis
    Yagihashi, K.
    Lynch, D. A.
    Huckleberry, J.
    Zach, J.
    Humphries, S.
    Yow, E.
    Flaherty, K. R.
    Tschirren, J.
    Van Beek, E. J.
    Kazerooni, E. A.
    Anstrom, K. J.
    Schwarz, M. I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [32] Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis
    Glaspole, Ian N.
    Watson, Alice L.
    Allan, Heather
    Chapman, Sally
    Cooper, Wendy A.
    Corte, Tamera J.
    Ellis, Samantha
    Grainge, Christopher
    Goh, Nicole
    Hopkins, Peter
    Keir, Gregory
    Macansh, Sacha
    Mahar, Annabelle
    Moodley, Yuben
    Reynolds, Paul N.
    Ryerson, Christopher J.
    Walters, E. Haydn
    Zappala, Christopher J.
    Holland, Anne E.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
  • [33] Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model
    King, TE
    Tooze, JA
    Schwarz, MI
    Brown, KR
    Cherniack, RM
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (07) : 1171 - 1181
  • [34] Exercise Testing, Pulmonary Hypertension And Survival In Patients With Idiopathic Pulmonary Fibrosis
    van der Plas, M. N.
    Wells, A.
    Blumenthal, J.
    Jansen, H. M.
    Bresser, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [35] LUNG TRANSPLANTATION AND SURVIVAL IN IDIOPATHIC PULMONARY FIBROSIS - AN IRISH PERSPECTIVE
    Riddell, P.
    Lawrie, I.
    Winward, S.
    Redmond, K.
    Egan, J. J.
    THORAX, 2013, 68 : A168 - A168
  • [36] SURFACTANT PROTEIN-A PREDICTS SURVIVAL IN IDIOPATHIC PULMONARY FIBROSIS
    MCCORMAC, FX
    KING, TE
    BUCHER, BL
    NIELSEN, L
    MASON, RJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (02) : 751 - 759
  • [37] Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis
    Miki, K
    Maekura, R
    Hiraga, T
    Okuda, Y
    Okamoto, T
    Hirotani, A
    Ogura, T
    RESPIRATORY MEDICINE, 2003, 97 (05) : 482 - 490
  • [38] Sleep Oxygen Desaturation Predicts Survival in Idiopathic Pulmonary Fibrosis
    Kolilekas, Likurgos
    Manali, Effrosyni
    Vlami, Katerina A.
    Lyberopoulos, Panagiotis
    Triantafillidou, Christina
    Kagouridis, Konstantinos
    Baou, Katerina
    Gyftopoulos, Sotirios
    Vougas, Konstantinos N.
    Karakatsani, Anna
    Alchanatis, Manos
    Papiris, Spyros
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2013, 9 (06): : 593 - 601
  • [39] Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
    de Andrade, Joao A.
    Neely, Megan L.
    Hellkamp, Anne S.
    Culver, Daniel A.
    Kim, Hyun J.
    Liesching, Timothy
    Lobo, Leonard J.
    Ramaswamy, Murali
    Safdar, Zeenat
    Bender, Shaun
    Conoscenti, Craig S.
    Leonard, Thomas B.
    Palmer, Scott M.
    Snyder, Laurie D.
    CLINICAL THERAPEUTICS, 2023, 45 (04) : 306 - 315
  • [40] Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
    Kaunisto, Jaana
    Salomaa, Eija-Riitta
    Hodgson, Ulla
    Kaarteenaho, Riitta
    Kankaanranta, Hannu
    Koli, Katri
    Vahlberg, Tero
    Myllarniemi, Marjukka
    ERJ OPEN RESEARCH, 2019, 5 (03)